Cite

An ethnographic exploration of the everyday lives of PwH reveals key themes including what PwH consider as ‘normal’, how PwH adapt to cope with uncertainties around treatment, and the unique challenges encountered by PwH at different life stages.
An ethnographic exploration of the everyday lives of PwH reveals key themes including what PwH consider as ‘normal’, how PwH adapt to cope with uncertainties around treatment, and the unique challenges encountered by PwH at different life stages.

Figure 1

Level of treatment burden, activity restriction, and joint problems across life-stages for PwHThe levels represented in this diagram are estimations based on an analysis of the disease-related challenges of respondents with haemophilia by age group. In the analysis, every patient challenge was recorded for each respondent, then grouped by challenge category (i.e. treatment burden, activity restriction, joint problems) and age group.
Level of treatment burden, activity restriction, and joint problems across life-stages for PwHThe levels represented in this diagram are estimations based on an analysis of the disease-related challenges of respondents with haemophilia by age group. In the analysis, every patient challenge was recorded for each respondent, then grouped by challenge category (i.e. treatment burden, activity restriction, joint problems) and age group.

Demographics of PwH in the study (n=51)All information in the table was self-reported by study participants.

PWH CHARACTERISTICSNPERCENTAGE
Age group
0–121631.4%
13–181019.6%
19–491427.5%
50+1121.6%
Country
UK1121.6%
Ireland 1223.5%
Germany 917.6%
Spain 917.6%
Italy 1019.6%
Disease type
Haemophilia A4282.4%
Haemophilia B917.6%
Disease severity
Mild or moderate 35.9%
Severe 4894.1%
Treatment regimen
Prophylaxis 4996.1%
On demand 23.9%
Adherence to prophylaxis treatment, all ages (n=49)
Never non-adherent 4081.6%
Rarely non-adherent 510.2%
Often non-adherent 48.2%
Adherence to prophylaxis treatment, age 0–18 (n=25)
Never non-adherent 25100%
Rarely non-adherent 00%
Often non-adherent 00%
Adherence to prophylaxis treatment, age 19–49 (n=13)
Never non-adherent 646.2%
Rarely non-adherent 430.8%
Often non-adherent 323.1%
Adherence to prophylaxis treatment, age 50+ (n=11)
Never non-adherent 981.8%
Rarely non-adherent 19.1%
Often non-adherent 19.1%
Medication
Standard half-life 3058.8%
Extended half-life 1529.4%
Non-factor-based 611.8%
Currently experiencing inhibitors
Yes 815.7%
No 4384.3%

Summary of PwH statistics

COURSEN=51PERCENTAGE
PwH who described their lives as normal 24 of 50148%
PwH who reported regular bleeds and/or joint pain, despite self-reported adherence to treatment 22 of 45249%
PwH who had experienced at least one bleed within the last year 32 of 5163%
PwH who reported disease-related limitations in activity levels 40 of 5178%
PwH who reported disease-related challenges with travel 17 of 5133%
PwH who stated that they tended to entrust their HCP with key decisions 39 of 50178%
PwH who described difficulty translating their HCP's concept of protection and activities based on factor levels into everyday life 26 of 50152%
PwH who described trying to ignore their condition, who were on prophylaxis, and were often or sometimes non-adherent 8 of 9389%
PwH who pointed to family members, patient organisations and summer camps as sources of information they use 20 of 50140%
PwH who reported that they obtain information from five or more different sources 15 of 50130%
eISSN:
2055-3390
Idioma:
Inglés
Calendario de la edición:
Volume Open
Temas de la revista:
Medicine, Basic Medical Science, other, Clinical Medicine, Pharmacy, Pharmacology